Genmab Corp (GMAB): Long-Term Debt to Capital Ratio

Genmab A/S (GMAB) relies on its unique DuoBody system and stable revenue from Darzalex to advance its oncology pipeline. However, geopolitical tensions and sanctions are currently hindering biomaterial logistics and global trials. The confirmed price history on this chart, where the indicator stands at 0.80, underscores the effectiveness of the Danish management, which has successfully balanced scientific research with the commercialization of antibodies.

GMAB - Genmab A/S Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Genmab A/S (GMAB) - metric breakdowns and financial figures

- price and consensus price forecast:

Market Price Genmab AS|GMAB - Price Target Chart

- market capitalization data:

Market Capitalization Genmab A/S|GMAB - Enterprise Value

- book capitalization data:

Accounting Value per Share Genmab|GMAB - Company Book Value|Market-to-Book Ratio genmab.com|GMAB - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Genmab A/S|GMAB - Long-Term Debt to Equity|Current Liabilities to Capital genmab.com|GMAB - Company Aggregate Debts|Debt to Net Assets Genmab A/S

Fundamental company valuation:GMAB Genmab AS

This metric determines the proportion of long-term borrowings relative to equity, measuring the degree of financial leverage and the stability of the funding structure during periods of rate volatility. By analyzing the long-term debt-to-equity ratio, investors assess the ability of Genmab A/S (GMAB) to scale oncology developments, utilizing colossal royalties from Darzalex to optimize the debt load without compromising investment potential.

Who Genmab A/S competes with